A screenshot from Noom's website. (Sherwood News)

Lilly cuts partnership with Noom in latest salvo in war on compounded GLP-1s

The end of the partnership marks the latest schism between drugmakers and telehealth providers.

7/25/25 4:42PM

Eli Lilly has terminated its partnership with Noom after the telehealth platform continued to sell knockoff versions of blockbuster GLP-1 drugs.

Lilly’s pharmacy provider “has notified Noom that it is terminating Noom’s LillyDirect platform integration,” a spokesperson for the company told Sherwood News on Friday. The partnership with Noom was announced in March and allowed patients on the platform access to vials of Lilly’s blockbuster weight-loss drug Zepbound, which are cheaper than the pens typically sold.

Noom has recently promoted “microdosed” GLP-1 treatments, using compounded versions of the diabetes and weight-loss medication. Lilly has previously said that part of its deals with telehealth partners are that they don’t continue selling knockoff versions of GLP-1s.

Noom did not immediately respond to a request for comment.

Telehealth companies like Hims & Hers and Noom began selling copies of the popular weight-loss drugs while they were in shortage but were supposed to stop selling them at scale when supply issues waned earlier this year.

Lilly and Novo Nordisk, which makes rival weight-loss drugs, struck deals with several telehealth companies in what they described as an effort to transition patients who were on compounded versions of their drugs to the name-brand version. But some telehealth companies, which can make more money selling knockoffs compared to shifting customers to the name-brand version, have quietly continued to offer compounded versions.

The end of Lilly’s partnership with Noom marks the latest schism between drugmakers that manufacture the massively popular drugs and the telehealth companies that have helped expand their reach.

Novo Nordisk has partnerships with telehealth providers. In June, Novo abruptly said it was calling off its deal with Hims & Hers and accused the company of “illegal mass compounding and deceptive marketing.”

Nia Warfield

Fox and News Corp slide as investors digest $3.3 billion Murdoch succession settlement

Fox and News Corp shares dropped on Tuesday after Rupert Murdoch’s heirs agreed to a $3.3 billion settlement to resolve a long-running succession drama.

Under the deal, Prudence, Elisabeth, and James Murdoch will each receive about $1.1 billion, paid for in part by Fox selling 16.9 million Class B voting shares and News Corp selling 14.2 million shares. The stock sales will raise roughly $1.37 billion on behalf of the three heirs.

The new trust for Lachlan Murdoch will now control about 36.2% of Fox’s Class B shares and roughly 33.1% of News Corp’s stock, granting him uncontested voting authority over both companies for the next 25 years. Originally, the Murdoch trust was designed to hand over voting control of Fox and News Corp to Prudence, Elisabeth, Lachlan, and James after his death.

Investors are weighing the trade-off. Clear leadership under Lachlan may resolve conflict internally, but the share dilution, executed at a roughly 4.5% discount, means long-term investors now hold slightly less clout than before.

Both companies’ stocks were trading close to all-time highs prior to the announcement.

385 ✈️ 434

Max Knoblauch

Boeing on Tuesday announced that it delivered 57 commercial jets in August, its best total for the month in seven years. That brings its year-to-date delivery total to 385 planes, eclipsing its full-year 2024 figure by about 11%.

The August figure marked Boeing’s second-highest delivery total of 2025 and represented a 43% jump from the same month last year. Through August, Boeing has boosted its deliveries by 50% from last year.

The plane maker is still trailing its European rival Airbus, which delivered 61 planes in August and 434 year to date.

Nia Warfield

9/8/25

Tariffs finally crept into retail's latest earnings results. Who were the winners and losers?

The long-awaited levies took a toll on nearly every retailer, but execution separated who could steer through the costs.